| MORPHOSYS AG O.N. | 89.20 / -2.98% |
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire - Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
09/13/2018 / 22:04 - GlobeNewswire - Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
09/13/2018 / 22:01 - GlobeNewswire - MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
09/12/2018 / 22:03 - GlobeNewswire - MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
09/12/2018 / 22:01 - GlobeNewswire - MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
07/19/2018 / 07:17 - GlobeNewswire - Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis
07/19/2018 / 07:15 - GlobeNewswire - MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
07/19/2018 / 07:15 - GlobeNewswire - Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
05/01/2018 / 22:03 - GlobeNewswire - Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
05/01/2018 / 22:01 - GlobeNewswire - Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
04/19/2018 / 22:25 - GlobeNewswire
Real-time